Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non-Current Deferred Tax Liability (2023 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $320000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deferred Tax Liability fell 29.98% year-over-year to $320000.0, compared with a TTM value of $320000.0 through Sep 2025, down 29.98%, and an annual FY2024 reading of $438000.0, down 23.69% over the prior year.
  • Non-Current Deferred Tax Liability was $320000.0 for Q3 2025 at Barinthus Biotherapeutics, down from $391000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $574000.0 in Q4 2023 and bottomed at $320000.0 in Q3 2025.
  • Average Non-Current Deferred Tax Liability over 3 years is $432666.7, with a median of $427000.0 recorded in 2024.
  • The sharpest move saw Non-Current Deferred Tax Liability dropped 23.69% in 2024, then decreased 29.98% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at $574000.0 in 2023, then decreased by 23.69% to $438000.0 in 2024, then dropped by 26.94% to $320000.0 in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for BRNS at $320000.0 in Q3 2025, $391000.0 in Q2 2025, and $416000.0 in Q1 2025.